Coloplast A/S Series B chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 101.67
Dividend & YieldN/A£ (N/A)
Beta 0.24
Market capitalization N/A
Operating cash flow 4.91B
ESG Scores 14.6

Company description

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

Sector: - Industry:

Financial data

Financial Statements

Cashflow Statement 2018-09-30 2019-09-30 2020-09-30 2021-09-30
Change To Liabilities -860M 145M 120M 224M
Total Cashflows From Investing Activities -947M -591M -901M -2.01B
Net Borrowings -96M -196M -152M 848M
Total Cash From Financing Activities -3.43B -3.71B -3.86B -3.18B
Change To Operating Activities 552M -17M -150M 97M
Issuance Of Stock 454M 380M 407M 306M
Net Income 3.85B 3.87B 4.2B 4.83B
Change In Cash -17M 59M -33M 125M
Effect Of Exchange Rate
Total Cash From Operating Activities 4.36B 4.36B 4.76B 5.29B
Depreciation 590M 618M 810M 745M
Change To Account Receivables -26M -222M 81M -235M
Other Cashflows From Financing Activities
Change To Netincome 313M 124M 63M -252M
Capital Expenditures -616M -617M -846M -919M

Income Statement 2018-09-30 2019-09-30 2020-09-30 2021-09-30
Research Development 640M 692M 708M 755M
Income Before Tax 5.01B 5.03B 5.47B 6.23B
Net Income 3.85B 3.87B 4.2B 4.83B
Selling General Administrative 5.37B 5.96B 6.08B 6.25B
Gross Profit 11.12B 12.2B 12.61B 13.31B
Ebit 5.14B 5.58B 5.85B 6.34B
Operating Income 5.14B 5.58B 5.85B 6.34B
Interest Expense -12M -6M -30M -25M
Income Tax Expense 1.16B 1.16B 1.27B 1.41B
Total Revenue 16.45B 17.94B 18.54B 19.43B
Cost Of Revenue 5.33B 5.74B 5.93B 6.11B
Total Other Income ExpenseNet -131M -548M -381M -104M
Net Income From Continuing Ops 3.85B 3.87B 4.2B 4.83B
Net Income Applicable To Common Shares 3.85B 3.87B 4.2B 4.83B

Balance Sheet Statement 2018-09-30 2019-09-30 2020-09-30 2021-09-30
Total Liabilities 5.35B 5.82B 6.09B 7.67B
Total Stockholder Equity 6.42B 6.91B 7.41B 8.17B
Other Current Liabilities 2.68B 3B 2.83B 2.93B
Total Assets 11.77B 12.73B 13.5B 15.84B
Common Stock 216M 216M 216M 216M
Other Current Assets 12M 13M
Retained Earnings 6.4B 6.92B 7.5B 8.38B
Treasury Stock -197M -228M -315M -433M
Cash 297M 356M 323M 448M
Total Current Liabilities 4.71B 4.94B 4.98B 6.31B
Other Stockholder Equity -197M -228M -315M -433M
Property, Plant, and Equipment 2.9B 2.84B 3.16B 3.58B
Total Current Assets 5.59B 6.36B 6.49B 6.99B
Net Tangible Assets 3.95B 4.46B 5.12B 4.6B
Net Receivables 3.08B 3.58B 3.51B 3.72B
Accounts Payable 751M 859M 814M 1.04B


Insider Transactions

Here are the insider transactions of stock shares related to Coloplast A/S Series B:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Coloplast A/S Series B. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Coloplast A/S Series B

Here is the result of two systematic investment strategies applied to Coloplast A/S Series B. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Coloplast A/S Series B

The following chart shows the equity curve of the two systematic investment strategies applied to Coloplast A/S Series B:

Coloplast A/S Series B automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Coloplast A/S Series B

This is the result of two momentum investment strategies applied to Coloplast A/S Series B. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Coloplast A/S Series B

The following chart shows all the entries opened by the momentum investment system on Coloplast A/S Series B:

Coloplast A/S Series B momentum entries
  • The first momentum investment strategy would give 8.88% of return on Coloplast A/S Series B. That represents 87.4£ of latent gain with 984.2£ of employed capital.
  • The second momentum investment strategy would give 0% of return on Coloplast A/S Series B. That represents 0.0£ of latent gain with 0.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

8.88 %

Latent gain

87.4 £

Invested capital

984.2 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Momentum equity curve on Coloplast A/S Series B

The following chart shows the equity curve of the two momentum strategies applied to Coloplast A/S Series B:

Coloplast A/S Series B momentum equity

Note: the dividends potentially given by Coloplast A/S Series B are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Coloplast A/S Series B

The following chart shows the employed capital evolution of the two momentum strategies on Coloplast A/S Series B since the beginning:

Coloplast A/S Series B

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on Coloplast A/S Series B

Buy the dip entry openings on Coloplast A/S Series B

Coloplast A/S Series B

The performance achieved by the robo-advisor on Coloplast A/S Series B is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows Coloplast A/S Series B stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Coloplast A/S Series B, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to Coloplast A/S Series B

The following chart shows the result of the investment strategy applied to Coloplast A/S Series B:

Coloplast A/S Series B

Note: the dividends potentially given by Coloplast A/S Series B are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Coloplast A/S Series B

The following chart shows the employed capital evolution since the beginning of the investment strategy on Coloplast A/S Series B:

Coloplast A/S Series B

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Coloplast A/S Series B

In this section, I will compare the three previous investment strategies applied to Coloplast A/S Series B.

Equity curve comparison on Coloplast A/S Series B

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Coloplast A/S Series B investment strategy comparison

Employed capital comparison on Coloplast A/S Series B

Coloplast A/S Series B investment comparison

Performance comparison on Coloplast A/S Series B

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0£ 0.0£ 0.0%
Momentum 1 quarter 8.88% 87.4£ 984.2£ 148.0%
Momentum 2 quarters 0% 0.0£ 0.0£ -0.0%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Coloplast A/S Series B:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Coloplast A/S Series B and the other stocks. There may be false positives or some missing correlated stocks. If the price of Coloplast A/S Series B does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Coloplast A/S Series B
Country Denmark
City Humlebæk
Address Holtedam 1-3
Phone 45 49 11 11 11
Website www.coloplast.com
FullTime employees 14000
Industry
Sector
Exchange XLON
Ticker 0QBO.XLON
Market www.londonstockexchange.com

Coloplast A/S Series B ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 1.5
Peer Environment Performance 2.2440350877193
Environment Percentile unknown
Palm Oil no
Nuclear no
Fur Leather no
GMO no
Coal no
Pesticides no
Animal Testing yes

Social scores

Social ESG Factors Scores
Social Score 7.1
Peer Social Performance 12.085087719298
Social Percentile unknown
Highest Controversy 2
Peer Highest Controversy Performance 1.9310344827586
Adult no
Gambling no
Alcoholic no
Tobacco no
Catholic no
Controversial Weapons no
Small Arms no
Military Contract no
Peer Count yes

Related Controversy: Customer Incidents


Governance scores

Governance ESG Factors Scores
Governance Score 6.0
Peer Governance Performance 7.7398245614035
Governance Percentile unknown

ESG at glance
Total ESG Scores: 14.6
Environment Score: 1.5
Social Score: 7.1
Governance Score: 6.0

ESG Performance: UNDER_PERF

Peer Group: Healthcare

Peer Esg Score Performance: 22.091551724138

Rating Year: 2022

Rating Month: 8

Max Age: 86400

Percentile: 9